How Gilead Lost $7.8B in October Alone Post author:Sam Post published:November 2, 2017 Post category:BioPharma Gilead Sciences’ third-quarter financial results were dismal, to say the least. Source: BioSpace You Might Also Like Vivasure Medical Enrolls First Patient In Frontier IV Clinical Trial October 12, 2017 Celgene To Announce Second Quarter 2017 Results On July 27, 2017 July 4, 2017 Celgene ReleaseData Presented At 2017 Further Evaluate Role Of ABRAXANE For Patients With Historically Challenging Cancers September 7, 2017
Celgene ReleaseData Presented At 2017 Further Evaluate Role Of ABRAXANE For Patients With Historically Challenging Cancers September 7, 2017
